Skip to main content

Advertisement

Table 2 The clinical characteristics of the 220 non-small cell lung cancer (NSCLC) patients

From: Association between DNA mismatch repair gene polymorphisms and platinum-based chemotherapy toxicity in non-small cell lung cancer patients

Variate Number of patients [cases (%)]
Total 220
Age (years)  
 ≤55 93 (42.3)
 >55 127 (57.7)
Smoking status  
 Never 95 (43.2)
 Ever 125 (56.8)
Gender  
 Male 165 (75.0)
 Female 55 (25.0)
ECOG PS  
 0–1 39 (17.7)
 2 181 (82.3)
Histological type  
 Adenocarcinoma 108 (49.1)
 Squamous cell carcinoma 112 (50.9)
Stage  
 I–II 8 (3.6)
 III–IV 212 (96.4)
Platinum-based drug  
 Cisplatin 37(16.8)
 Carboplatin 183 (83.2)
Chemotherapy regimen  
 Platinum-gemcitabine 112 (50.9)
 Platinum-pemetrexed 68 (30.9)
 Platinum-paclitaxel 23 (10.4)
 Platinum-docetaxel 12 (5.5)
 Platinum-navelbine 5 (2.3)
Severe toxicity  
 Total 79 (35.9)
 Hematologic toxicity 55 (25.0)
 Gastrointestinal toxicity 31 (14.1)
  1. ECOG Eastern Cooperative Oncology Group, PS performance status